Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.
What happened
FDA conducted an unannounced inspection of Patcos Cosmetics' drug manufacturing facility in Daman, India, from July 14 to 18, 2025. Investigators observed insanitary conditions, including harborage areas, a broken window, water damage, mold-like residue, and production-area sinks used as a water source for cleaning equipment. FDA also cited CGMP violations for inadequate identity testing of high-risk components, poor system and process validation, quality-unit failures, and data integrity problems, and it found the company's August 11, 2025, response inadequate.
What FDA found
Drug products were prepared, packed, or held under insanitary conditions that could contaminate them with filth or make them injurious to health.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)The firm failed to keep buildings used for drug manufacturing in a good state of repair, with dirt, water damage, and mold-like residue in production and storage areas.
21 CFR 211.58The firm failed to conduct at least one identity test for each incoming component lot, including high-risk components, and its third-party test methods were not validated or verified.
21 CFR 211.84(d)(1)The firm failed to establish adequate written production and process controls, including adequate validation and monitoring of a manufacturing system and validation of manufacturing processes, and some batches were super potent.
21 CFR 211.100(a)The quality unit failed to oversee laboratory data, batch records, specifications, and stability testing, including failing to prevent alteration of original data to conceal out-of-specification results.
21 CFR 211.22(a) and (d)The firm lacked adequate data integrity controls, including deliberate alteration of original laboratory data.
21 CFR 211.194
What FDA wants
FDA tells Patcos to provide comprehensive facility, system, process-validation, quality-unit, and data-integrity remediation plans, plus risk assessments and customer notifications or recalls for affected lots. It also asks for high-risk component test results within 30 calendar days.
Who should pay attention
- brands and distributors that buy OTC drugs from this contract manufacturer
- companies sourcing ingredients or finished products from Indian drug manufacturers
- quality teams managing supplier qualification and data integrity
This is a summary. Read the original letter on fda.gov.